New Guideline Gives Active Surveillance a Boost
The 2022 guidance for the first time makes active surveillance the recommended treatment for select patients with favorable intermediate-risk Gleason 3+4 prostate cancer.
Source: medscape.com
📰 James Schraidt News
James Schraidt News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from James Schraidt. Real-time updates on events, politics, business and more.